Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

OKYO Pharma Limited - Ordinary Shares (NQ:OKYO)

2.130 -0.010 (-0.47%)
Streaming Delayed Price Updated: 3:59 PM EST, Nov 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about OKYO Pharma Limited - Ordinary Shares

< Previous 1 2 3 4 Next >
News headline image
OKYO Pharma Announces Proposed Public Offering of Ordinary Shares
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Limited Receives Nasdaq Deficiency Notice
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Now Participating on the Webull Corporate Communications Service Platform
Webull’s community of active participants can now access OKYO's profile on the leading mobile-first brokerage platform 
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited
Via ACCESSWIRE
News headline image
OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023
From OKYO Pharma LTD
Via GlobeNewswire
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:NVS),(NASDAQ:ALDX),(NASDAQ:OCUL),(NASDAQ:EYPT) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay
Via ACCESSWIRE
News headline image
Notice of General Meeting and Publication of Circular
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
Notice of Intention to Delist From The London Stock Exchange
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Today Announces Director Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Today Announces Director Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4
By David Willey, Benzinga 
Via TheNewswire.com
News headline image
OKYO Pharma Announces PDMR Dealing
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials.gov Public Website
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Limited announces U.S.$5.74 million Global Private Placement and investment by directors and members of senior management
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Limited Prices $5.3 Million Offering of ADSs
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
SmallCapsDaily Interviews OKYO Pharma CEO Dr. Gary Jacob, PHD
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease
From OKYO Pharma LTD
Via GlobeNewswire
Dry Eye Disease Impacts 49 Million Americans And Disproportionately Affects Women, But Current Treatments Aren't Fully Effective – OKYO Pharma's Drug Candidate Could Be The Solution
By David Willey, Benzinga 
Via TheNewswire.com
News headline image
OKYO Pharma Announces Appointment of Dr. Jay S. Pepose to Its Scientific Advisory Board
World-renowned Ophthalmologist with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Joins Advisory Board of OKYO Pharma 
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma to Present at the Second Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA on February 21-23, 2023.
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Limited - Interim Results for the Six Months Ending 30 September 2022
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO to Participate at Biotech Showcase
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Limited ("OKYO" or the "Company") - OKYO publicly files a registration statement with the SEC
From OKYO Pharma LTD
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.